The PROTEMBO C Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-31

Study Completion Date

2022-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The PROTEMBO C Trial is an international, multi-center, single arm, non-inferiority study of the safety and performance of using the ProtEmbo System for cerebral embolic protection in subjects with severe native aortic valve stenosis indicated for TAVR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

NCT01531374

Severe Aortic Stenosis

COMPLETED NA

A Prospective, Multicenter, Observational Study of the Safety and Efficacy of Emergency Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis

NCT07108478

Severe Aortic Valve Stenosis

NOT_YET_RECRUITING

TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis

NCT06597188

Aortic Stenosis Bicuspid Aortic Valve (BAV)

ENROLLING_BY_INVITATION NA

FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System

NCT03417011

Aortic Valve Stenosis

COMPLETED

Portico Next Generation Approval Study

NCT04011722

Symptomatic Severe Aortic Stenosis

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Valvular Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

ProtEmbo device will be used as distal protection device in subjects undergoing TAVR

Group Type EXPERIMENTAL

cerebral embolic protection during TAVR

Intervention Type DEVICE

The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cerebral embolic protection during TAVR

The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The heart team recommends transcatheter valve aortic valve replace consistent with the 2017 ESC/EACTS Guidelines for the management of valvular heart disease.
2. Compatible left subclavian artery (≥ 4 mm diameter) without significant stenosis (\> 70%) and distance between the origin of left subclavian artery and valve plain of ≥ 90mm as determined by Multi-Slice Computed Tomography (MSCT) scan or equivalent imaging modality.
3. The subject and the treating physician agree that the subject will undergo the scheduled pre-procedural testing and return for all required post-procedure follow-up visits.
4. The subject is able to provide informed consent, has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the relevant regulatory authority of the respective clinical site.
5. Subject is a minimum of 18 years of age.

Exclusion Criteria

General:

1. Left upper limb vasculature in the left extremity precluding 6Fr sheath radial / brachial / subclavian access.
2. Inadequate circulation to the left extremity as evidenced by signs of artery occlusion (modified Allen's test) or absence of radial/brachial pulse.
3. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature.
4. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
5. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment.
6. Aortic valve is a congenital unicuspid or bicuspid valve.
7. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+).
8. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease).
9. Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy.
10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.
11. Need for emergency surgery for any reason.
12. Severe hypertrophic cardiomyopathy with or without obstruction.
13. Severe ventricular dysfunction with LVEF ≤30%.
14. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation.
15. Symptomatic or asymptomatic severe (≥ 70%) occlusive carotid disease requiring concomitant CEA / stenting.
16. Subject has undergone carotid stenting or carotid endarterectomy within the previous 6 weeks.
17. Active peptic ulcer or upper GI bleeding within the prior 6 months.
18. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or clopidogrel, device component material, or sensitivity to contrast media, which cannot be adequately premedicated.
19. Recent (within 6 months) CVA or a TIA.
20. Renal insufficiency (creatinine \> 3.0 mg / dL or GFR \< 30) and / or renal replacement therapy at the time of screening.
21. Life expectancy \< 12 months due to non-cardiac co-morbid conditions.
22. Subjects in whom anti-platelet and / or anticoagulant therapy is contraindicated, or who will refuse transfusion.
23. Subjects who have active bacterial endocarditis or other active infections.
24. Currently participating in an investigational drug or another device study.
25. Subjects who have a planned treatment with any other investigational device or procedure during the study follow-up period (30 days).
26. Subjects with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation during the study follow-up period (30 days).
27. Any subject with a balloon valvuloplasty (BAV) within 30 days of the procedure.
28. Subject is a woman of child-bearing potential.
29. Patient with Heparin-Induced Thrombocytopenia Syndrome.
30. Inner diameter of aortic arch is less than 25mm.
31. Brachiocephalic trunk originating from the aortic arch that splits into the bilateral subclavian arteries and a bicarotid trunk (Origin D).
32. Hepatic failure (defined as liver enzyme elevations two times the upper limit of normal) or active infectious hepatitis
33. Cardiogenic shock or severe hypotension (systolic blood pressure \< 90 mm Hg) at the time of the index procedure
34. Subjects who have a planned concomitant cardiac surgical or interventional procedure (e.g., coronary revascularization) during the TAVI procedure
35. Subjects who have a pre-existing prosthetic heart valve in any position

Neurological:

1. Subject had active major psychiatric disease.
2. Subject has severe visual, auditory, or learning impairment and is unable to comprehend English or local language and therefore unable to be consented for the study.
3. Subjects with neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

Angiographic:

1. Excessive tortuosity or severe peripheral arterial disease in the left radial / brachial / subclavian artery preventing ProtEmbo System access and insertion.
2. Subject whose left radial / brachial / subclavian artery reveals significant stenosis, calcification, ectasia, dissection, occlusion or aneurysm, in particular at or within 3 cm of the aortic ostium.
3. Subject with significant stenosis, ectasia, dissection, or aneurysm in the ascending aorta or in the aortic arch, or with abnormal aortic arch angulation or abnormal anatomical conditions of the aorta.

Magnetic Resonance Imaging:

1. Subject Body Mass Index (BMI) precluding imaging in scanner.
2. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
3. Subjects who have a high risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g. subjects with preexisting bifascicular block or complete right bundle branch block plus any degree of AV block).
4. Planned implantation of a pacemaker or defibrillator implantation within the first 4 days after TAVR.
5. Claustrophobia precluding MRI scanning.
6. No scanner hardware, software, coil or protocol changes during the course of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No